Dipeptidyl Peptidase 4 Inhibitor Sitagliptin Maintains β-Cell Function in Patients With Recent-Onset Latent Autoimmune Diabetes in Adults: One Year Prospective Study-Reference-Cited by-同舟云学术

Dipeptidyl Peptidase 4 Inhibitor Sitagliptin Maintains β-Cell Function in Patients With Recent-Onset Latent Autoimmune Diabetes in Adults: One Year Prospective Study

Published:2014-05-01 Issue:5 Volume:99 Page:E876-E880
ISSN:0021-972X
Container-title:The Journal of Clinical Endocrinology & Metabolism
language:en
Short-container-title:

Author:

Zhao Yunjuan¹,Yang Lin¹,Xiang Yufei¹,Liu Lingjiao¹,Huang Gan¹,Long Zhaofeng¹,Li Xia¹,Leslie R. David²,Wang Xiangbing³,Zhou Zhiguang¹

Affiliation:

1. Diabetes Center (Y.Z., L.Y., Y.X., L.L., G.H., Z.L., X.L., Z.Z.), Institute of Metabolism and Endocrinology, The Second Xiangya Hospital and Key Laboratory of Diabetes Immunology, Ministry of Education, Central South University, Changsha, Hunan 410011,

2. People's Republic of China; Department of Diabetes and Metabolic Medicine (R.D.L.), Blizard Institute, London E1 2AT, United Kingdom;

3. Division of Endocrinology, Metabolism, and Nutrition (X.W.), Rutgers University-Robert Wood Johnson Medical School, New Brunswick, New Jersey 08903

Publisher

The Endocrine Society

Subject

Biochemistry (medical),Clinical Biochemistry,Endocrinology,Biochemistry,Endocrinology, Diabetes and Metabolism

Link

http://academic.oup.com/jcem/article-pdf/99/5/E876/9050745/jcemE876.pdf

Reference20 articles.

1. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic β-cell mass and function in a rodent model of type 2 diabetes;Mu;Diabetes,2006

2. Reduction of both β cell death and α cell proliferation by dipeptidyl peptidase-4 inhibition in a streptozotocin-induced model of diabetes in mice;Takeda;Diabetologia,2012

3. Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes;D'Alessio;J Clin Endocrinol Metab,2009

4. β Cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia: a randomised controlled trial;Foley;Diabetologia,2011

5. The dipeptidyl peptidase-4 inhibitor vildagliptin improves β-cell function and insulin sensitivity in subjects with impaired fasting glucose;Utzschneider;Diabetes Care,2008

Cited by 110 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The efficacy and safety of Diptptidyl peptidase-4 inhibitors combined with insulin in patients with autoimmune diabetes: A updated meta-analysis;Endocrine and Metabolic Science;2024-06

2. PRE1BRAZIL Protocol: A Randomized Controlled Trial to Evaluate the Effectiveness and Safety of the DPP-4 Inhibitor Alogliptin in Delaying the Progression of Stage 2 Type 1 Diabetes;Diabetes, Metabolic Syndrome and Obesity;2024-02

3. Saxagliptin/dapagliflozin is non‐inferior to insulin glargine in terms of β‐cell function in subjects with latent autoimmune diabetes in adults: A 12‐month, randomized, comparator‐controlled pilot study;Diabetes, Obesity and Metabolism;2024-01-31

4. A Review on Latent Autoimmune Diabetes in Adults;Cureus;2023-10-29

5. Immunomodulatory activity of dipeptidyl peptidase‐4 inhibitors in immune‐related diseases;European Journal of Immunology;2023-09-28